CA3216642A1 - Compositions and methods for treating pediatric myasthenia gravis - Google Patents

Compositions and methods for treating pediatric myasthenia gravis Download PDF

Info

Publication number
CA3216642A1
CA3216642A1 CA3216642A CA3216642A CA3216642A1 CA 3216642 A1 CA3216642 A1 CA 3216642A1 CA 3216642 A CA3216642 A CA 3216642A CA 3216642 A CA3216642 A CA 3216642A CA 3216642 A1 CA3216642 A1 CA 3216642A1
Authority
CA
Canada
Prior art keywords
myasthenia gravis
seq
pediatric
administration
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3216642A
Other languages
English (en)
French (fr)
Inventor
Shawn Black
Sindhu Ramchandren
Yaowei ZHU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Momenta Pharmaceuticals Inc
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of CA3216642A1 publication Critical patent/CA3216642A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA3216642A 2021-04-12 2022-04-12 Compositions and methods for treating pediatric myasthenia gravis Pending CA3216642A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163173919P 2021-04-12 2021-04-12
US63/173,919 2021-04-12
US202163219155P 2021-07-07 2021-07-07
US63/219,155 2021-07-07
US202263266880P 2022-01-18 2022-01-18
US63/266,880 2022-01-18
PCT/US2022/024354 WO2022221239A1 (en) 2021-04-12 2022-04-12 Compositions and methods for treating pediatric myasthenia gravis

Publications (1)

Publication Number Publication Date
CA3216642A1 true CA3216642A1 (en) 2022-10-20

Family

ID=83640966

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3216642A Pending CA3216642A1 (en) 2021-04-12 2022-04-12 Compositions and methods for treating pediatric myasthenia gravis

Country Status (13)

Country Link
US (1) US20240182598A1 (cg-RX-API-DMAC7.html)
EP (1) EP4323002A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024517087A (cg-RX-API-DMAC7.html)
KR (1) KR20230169207A (cg-RX-API-DMAC7.html)
AU (1) AU2022256389A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023021046A2 (cg-RX-API-DMAC7.html)
CA (1) CA3216642A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003033A1 (cg-RX-API-DMAC7.html)
IL (1) IL307445A (cg-RX-API-DMAC7.html)
JO (1) JOP20230247A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023012032A (cg-RX-API-DMAC7.html)
PH (1) PH12023552841A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022221239A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019001806A2 (pt) 2016-07-29 2019-05-07 Momenta Pharmaceuticals, Inc. anticorpos para fcrn e métodos de uso dos mesmos
EA202190264A1 (ru) 2018-07-20 2021-05-20 Момента Фармасьютикалз, Инк. КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101540823B1 (ko) * 2007-03-30 2015-07-30 메디뮨 엘엘씨 항체 제제
JP6853178B2 (ja) * 2015-01-30 2021-03-31 モメンタ ファーマシューティカルズ インコーポレイテッド FcRn抗体およびその使用方法
MA51032A (fr) * 2017-12-08 2021-03-17 Argenx Bvba Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée
BR112020011310A2 (pt) * 2017-12-13 2020-11-17 Momenta Pharmaceuticals, Inc. anticorpos contra fcrn e seus métodos de uso
EP3762027A4 (en) * 2018-02-13 2022-06-15 The Brigham & Women's Hospital, Inc. THERAPEUTIC FCRN-BASED BISPECIFIC MONOCLONAL ANTIBODIES
IL280280B2 (en) * 2018-07-20 2024-11-01 Momenta Pharmaceuticals Inc Compositions of fcrn antibodies and methods of use thereof
JP7518821B2 (ja) * 2018-10-16 2024-07-18 ユーシービー バイオファルマ エスアールエル 重症筋無力症の治療方法

Also Published As

Publication number Publication date
AU2022256389A9 (en) 2023-12-07
KR20230169207A (ko) 2023-12-15
JOP20230247A1 (ar) 2023-10-12
MX2023012032A (es) 2023-12-08
JP2024517087A (ja) 2024-04-19
EP4323002A4 (en) 2025-04-16
PH12023552841A1 (en) 2024-05-20
WO2022221239A1 (en) 2022-10-20
BR112023021046A2 (pt) 2023-12-19
US20240182598A1 (en) 2024-06-06
AU2022256389A1 (en) 2023-11-30
CL2023003033A1 (es) 2024-03-08
IL307445A (en) 2023-12-01
EP4323002A1 (en) 2024-02-21

Similar Documents

Publication Publication Date Title
US11873336B2 (en) Heavy chain antibodies binding to CD22
US20240336691A1 (en) Anti-tl1a antibody compositions and methods of treatment in the lung
US20220144946A1 (en) Fcrn antibodies and methods of use thereof
US20250243289A1 (en) Methods of treating inflammatory diseases with combination of tl1a inhibitors and il23 inhibitors
US20240309104A1 (en) Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
KR20230130681A (ko) Il-4r 길항제 투여에 의한 땅콩 알레르기를 치료하는방법 및 땅콩 알레르기원 특이적 면역치료를 강화하는 방법
JP2021508366A (ja) 気分障害の治療及び診断のための抗−配列類似性19を持つファミリー、メンバーa5抗体の用途
US20240182598A1 (en) Compositions and methods for treating pediatric myasthenia gravis
US20250011417A1 (en) Methods for the treatment of thyroid eye disease
KR20260050360A (ko) 만성 갑상선 안질환의 치료 방법
US20250197511A1 (en) Methods for the treatment of thyroid eye disease
KR20240049351A (ko) Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
US20220041694A1 (en) Sars-cov-2 antibodies for treatment and prevention of covid-19
CA3130300A1 (en) Dosage and administration of anti-c5 antibodies for treatment of generalized myasthenia gravis
WO2025163617A1 (en) Compositions and methods for treating sjögren's disease
US20250340660A1 (en) Anti-cd30l antibodies, formulations therefor, and uses thereof
US11981745B2 (en) Anti-mesothelin antigen-binding molecules and uses thereof
EA052034B1 (ru) Композиции и способы лечения детской миастении гравис
CN117120092A (zh) 用于治疗儿科重症肌无力的组合物和方法
CN120051302A (zh) 用于治疗非活动性或慢性甲状腺眼病的方法
US20250066467A1 (en) Methods for the treatment of myasthenia gravis
JP2026501785A (ja) 自己免疫疾患の治療のための抗cd38抗体
CN120603605A (zh) 用于通过施用il-4r拮抗剂改善骨生长的方法
CN118302194A (zh) 用于治疗甲状腺眼病的组合物、剂量和方法
EA051865B1 (ru) Антитела к fcrn и способы их применения

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241224

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241224

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241224

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260303

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260303

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260410

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260410

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260410

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260422

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260422

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260422

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260422

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260423

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260423